Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset
Authors' conclusion
Anti-HK1 autoantibodies can be used as DME markers but fail to predict DME onset.
Study context
- Population
- Patients with diabetic macular edema (DME), diabetes mellitus (DM), allergies or autoimmunities, and control subjects
- Exposure
- Anti-HK1/anti-HK2 autoantibody positivity in DME vs DM, allergies or autoimmunities, and controls
- Outcome
- Anti-HK1 autoantibody positivity
Methodological detailsimmunoblotting, prospective follow-up up to nine years
- Immunoblotting
- Prospective follow-up up to nine years
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
- Anti-HK2 autoantibody positivity — DME
- 12 %
Anti-HK1 positivity in DME by underlying diabetes type
%
- DME with underlying T1D
- 42
- DME with underlying T2D
- 31
Anti-HK2 autoantibody positivity
- DM, allergies/autoimmunities and controls were anti-HK2 negative
- Only partial overlap of anti-HK1 and anti-HK2 positive DME patients
New-onset DME in initially anti-HK1 positive DM patients · up to nine years
- Developed DME among initially anti-HK1 positive DM patients
- one of seven
Original publication
Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset. Diabetes Res Clin Pract. Published 29 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →